Hummingbird Bioscience
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
- Company typePrivate
- Founded2014
- HeadquartersWoodlands, Singapore
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hummingbird Bioscience does
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.
Hummingbird Bioscience firmographics
Firmographics- Name
- Hummingbird Bioscience
- Legal name
- Hummingbird Bioscience Ltd.
- Website
- http://www.hummingbirdbioscience.com/en/
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
- Ownership category
- akta.pro rank
Hummingbird Bioscience industry classification
Industry- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industry
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Hummingbird Bioscience is headquartered
LocationHeadquarters
- HQ city
- Woodlands
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
Hummingbird Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Licensing Agreements: Hummingbird licenses its proprietary antibody programs to partner companies for further development and commercialization, receiving upfront payments, milestone payments, and royalties.
- Strategic Investments: Company participates as an investor in complementary biotech companies, receiving equity stakes and potential future returns.
- Co-development Partnerships: Collaborative development arrangements where Hummingbird contributes its technology platforms and drug candidates while partners provide funding, development expertise, and commercialization capabilities.
- Research Grants: Non-dilutive funding from government agencies such as Cancer Prevention and Research Institute of Texas (CPRIT) to support specific research and clinical development programs.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Hummingbird Bioscience product offering
Product offeringCore offering
Hummingbird Bioscience discovers and develops precision antibody-based therapeutics, including monoclonal antibodies and antibody-drug conjugates, for hard-to-treat cancers and autoimmune diseases. Its pipeline is powered by a proprietary Rational Antibody Discovery platform combining AI-driven computational biology (mAbPredictAI) with immunoengineering (mAbHits Abvantage), and an ADC platform using proprietary linker-payload technologies. The company monetizes its pipeline through out-licensing and co-development partnerships with pharmaceutical and biotech companies.
Product overview
Hummingbird Bioscience is a data-driven precision biotherapeutics company developing a portfolio of clinical-stage antibody-based therapeutics for hard-to-treat diseases, particularly cancer. The company's pipeline includes HMBD-001 (anti-HER3 monoclonal antibody), HMBD-002 (anti-VISTA monoclonal antibody licensed to Percheron Therapeutics), and HMBD-501 (HER3-targeting ADC), alongside partnered programs (HMBD-802, HMBD-803, HMBD-804 licensed to Callio Therapeutics, and HMBD-011). These programs are powered by the company's proprietary Rational Antibody Discovery (RAD) platform, which integrates AI-powered computational biology (mAbPredictAI) with immunoengineering capabilities (mAbHits Abvantage), and an ADC Platform utilizing proprietary linker-payload technologies for next-generation antibody-drug conjugate development.
Differentiator
Problem solved
Functional benefit
Brands
- mAbPredictAI: AI-powered computational biology platform for integrated analysis of multidisciplinary data to produce validated insights into disease biology and predict optimal epitopes for antibody development.
- mAbHits Abvantage™
Quantifiable outcome
- More than 80% tumor growth inhibition observed in preclinical models with common HER3 mutations
- +2 more outcomes
Companies that use Hummingbird Bioscience
Customer profileNamed customers2 records
Segments4 records
Hummingbird Bioscience technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Hummingbird Bioscience partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, undisclosed and moderate.
- Percheron TherapeuticscorePercheron Therapeutics licensed HMBD-002 (Phase II-ready anti-VISTA monoclonal antibody) from Hummingbird Bioscience in June 2025. Percheron is advancing the asset through Phase II trials targeting triple-negative breast cancer as the priority indication, with Q4 2026 trial commencement targeted. Percheron completed GMP drug substance production in June 2026 under the licensing agreement.
- Callio TherapeuticscoreCallio Therapeutics licensed three ADC programs from Hummingbird Bioscience: HMBD-802 (HER2-targeted dual-payload ADC), HMBD-803, and HMBD-804 (both undisclosed targets). These programs are partnered as part of Callio's ADC pipeline.
- Undisclosed PartnerundisclosedHMBD-011 (VH4-34 targeting monoclonal antibody) is licensed to an undisclosed party for development in oncology and autoimmune indications.
- Geisel School of Medicine at DartmouthmoderateHummingbird Bioscience and Dartmouth's Geisel School of Medicine co-host the annual Virtual VISTA Symposium, bringing together researchers to discuss VISTA biology and therapeutic potential.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Hummingbird Bioscience competitors and assessment
Company assessmentBroad incumbents
- BeiGene: Global oncology-focused biotechnology company developing both small molecules and antibody therapeutics including ADCs. While much larger and more diversified, BeiGene shares Hummingbird's oncology focus and antibody-based therapeutic approach.
Direct peers
- Compass Therapeutics: Clinical-stage antibody oncology company developing both naked antibodies and ADCs with platform-driven discovery. Compass's pipeline structure (multiple antibody programs in oncology, licensing-driven business model) closely parallels Hummingbird's approach.
- AbCellera Biologics: Antibody discovery platform company combining AI/computational biology with high-throughput wet lab capabilities to generate therapeutic antibodies. Both companies operate technology-platform business models monetizing antibody discovery through partnerships.
- Schrödinger: Computational drug discovery platform company using physics-based modeling and AI for drug design across multiple modalities. Both companies leverage computational biology as a core differentiator for therapeutic discovery, though Schrödinger spans small molecules and biologics.
- Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Pyxis's ADC pipeline and oncology focus (including tumor-microenvironment targeting) overlaps directly with Hummingbird's HMBD-501 and partnered ADC programs.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology, chemistry, and machine learning to identify novel therapeutics. Similar to Hummingbird's mAbPredictAI approach, Recursion uses AI for target identification and drug design, though with broader therapeutic scope.
- Exscientia: AI-native drug discovery company combining patient biology data with AI for precision medicine design. Both companies emphasize integration of AI with patient biology for precision therapeutics, though Exscientia focuses more on small molecules.
- Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing antibody-based therapeutics including next-generation ADCs and immune-stimulating conjugates. Bolt's pipeline and oncology focus directly parallel Hummingbird's HMBD-001 and ADC programs.
- ProfoundBio: Clinical-stage biotech developing next-generation ADCs with proprietary linker-payload technologies for oncology. ProfoundBio's ADC platform approach — combining novel payloads with antibody targeting — directly competes with Hummingbird's HMBD-802/501 ADC programs.
- Dragonfly Therapeutics: Biotechnology company developing antibody-based immunotherapies for cancer and autoimmune diseases using proprietary platform technology. Dragonfly's platform-driven antibody approach (TriNKETs, cytokine therapies) parallels Hummingbird's platform-based discovery model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Hummingbird Bioscience social profiles
Digital presenceHummingbird Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hummingbird Bioscience leadership team
Management profileNumber of profiles
Hummingbird Bioscience subsidiaries and ownership
Company hierarchySubsidiaries1 record
Hummingbird Bioscience funding detail
Funding detailFunding overview
Funding rounds3 records
Investors23 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hummingbird Bioscience M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hummingbird Bioscience
What does Hummingbird Bioscience do?
Hummingbird Bioscience discovers and develops precision antibody-based therapeutics, including monoclonal antibodies and antibody-drug conjugates, for hard-to-treat cancers and autoimmune diseases. Its pipeline is powered by a proprietary Rational Antibody Discovery platform combining AI-driven computational biology (mAbPredictAI) with immunoengineering (mAbHits Abvantage), and an ADC platform using proprietary linker-payload technologies. The company monetizes its pipeline through out-licensing and co-development partnerships with pharmaceutical and biotech companies.
Is Hummingbird Bioscience a public or private company?
Hummingbird Bioscience is a private company. It is currently operating.
When was Hummingbird Bioscience founded?
Hummingbird Bioscience was founded in 2014. It employs 51 to 100 people.
Where is Hummingbird Bioscience based?
Hummingbird Bioscience is headquartered in Woodlands, Singapore, in the Asia region.
How does Hummingbird Bioscience make money?
Four revenue lines are on record. Licensing Agreements are the primary driver. The others are strategic Investments, co-development Partnerships and research Grants.
Who are Hummingbird Bioscience's main competitors?
BeiGene is listed as a broad incumbent. Direct peers are Compass Therapeutics, AbCellera Biologics, Schrödinger, Pyxis Oncology, Recursion Pharmaceuticals, Exscientia, Bolt Biotherapeutics, ProfoundBio and Dragonfly Therapeutics.
Does Hummingbird Bioscience have an API?
No public API is recorded for Hummingbird Bioscience.
What industry is Hummingbird Bioscience in?
Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 541714 and its SIC code is 2836.